Strain Name:

B6.129P2-Trp53tm1Brn/J

Stock Number:

008462

Order this mouse

Availability:

Repository- Live

When these p53flox mice are bred to mice with a Cre recombinase gene under the control of a promoter of interest, Trp53 expression is deleted in the tissue of interest.

Description

Strain Information

Type Congenic; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Mating SystemHomozygote x Homozygote         (Female x Male)   13-DEC-11
Specieslaboratory mouse
GenerationN8+N2F0 (23-APR-13)
Generation Definitions
 
Donating InvestigatorDr. Anton Berns,   University of Amsterdam

Description
Exons 2-10 are flanked by loxP sites in this conditional targeted mutation. Mice homozygous for the floxed allele do not show any increase in disease incidence for at least a year. When bred to mice with a cre recombinase gene under the control of a promoter of interest, expression is deleted in the tissue of interest.

For example, when crossed to a strain expressing Cre recombinase in the nervous system (see Stock No. 003771), this mutant mouse strain may be useful in studies of medulloblastoma formation.

When crossed to a strain expressing Cre recombinase in the central nervous system (see Stock No. 004600), this mutant mouse strain may be useful in studies of astrocytoma formation.

When crossed to a strain expressing Cre recombinase in virgin and lactating mammary glands (see Stock No. 003553), this mutant mouse strain may be useful in studies of mammary gland tumors.

When crossed to a strain expressing a doxycyclin-inducible Cre recombinase in the osteoblast lineage (see Stock No. 006361), this mutant mouse strain may be useful in studies of osteosarcomas.

Development
A targeting vector was used to introduce flanking loxP sites to introns 1 and 10 of the gene. An IB10/E14IB10 129P2/OlaHsd-derived embryonic stem cell line was used to create the mutation. This line has been backcrossed to C57BL/6 for eight generations by the donating laboratory of Dr. Tyler Jacks (see SNP note below).

A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, 2 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a mixed C57BL/6J ; C57BL/6N genetic background.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Related Strains

View Strains carrying other alleles of Trp53     (27 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Osteogenic Sarcoma
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Adrenocortical Carcinoma, Hereditary; ADCC   (TP53)
Basal Cell Carcinoma, Susceptibility to, 7; BCC7   (TP53)
Breast Cancer   (TP53)
Colorectal Cancer; CRC   (TP53)
Glioma Susceptibility 1; GLM1   (TP53)
Hepatocellular Carcinoma   (TP53)
Li-Fraumeni Syndrome 1; LFS1   (TP53)
Nasopharyngeal Carcinoma   (TP53)
Pancreatic Cancer   (TP53)
Papilloma of Choroid Plexus; CPP   (TP53)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain.

Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd   (conditional)
  • cellular phenotype
  • *normal* cellular phenotype
    • ovarian surface epithelium (OSE) cells do not show any enhancement of proliferation after adenoviral cre treatment   (MGI Ref ID J:117113)
    • abnormal cell physiology
      • ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit increased cell motility and invasion compared with cells transfected with a lacZ-expressing adenovirus   (MGI Ref ID J:175978)
      • abnormal cell death
        • after adenoviral cre infection, OSE cells in culture show significantly higher sensitivity to cisplatin treatment compared to control cells (31% remain ater 48 hours compared to 40% of control cells remaining)   (MGI Ref ID J:117113)
      • abnormal cell migration
        • ovarian surface epithelium cells transfected with a cre-expressing adenovirus exhibit increased cell motility compared with cells transfected with a lacZ-expressing adenovirus   (MGI Ref ID J:175978)
  • tumorigenesis
  • increased lung adenocarcinoma incidence
    • in 6 of 7 mice following treatment with cre-expressing adenovirus   (MGI Ref ID J:157319)
  • homeostasis/metabolism phenotype
  • enhanced wound healing
    • ovarian surface epithelium cells with a cre-expressing adenovirus exhibit enhanced wound closure compared with cells transfected with a lacZ-expressing adenovirus   (MGI Ref ID J:175978)

Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd * FVB/N
  • normal phenotype
  • no abnormal phenotype detected
    • mice are normal   (MGI Ref ID J:73028)

Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd * FVB/N   (conditional)
  • endocrine/exocrine gland phenotype
  • ovary cysts
    • 2 of 7 mice injected with an adenovirus expressing cre recombinase into the bursa develop bursal cysts 6 months after injection   (MGI Ref ID J:200783)
    • however, mice injected with an adenovirus expressing cre recombinase into the oviduct exhibit no change in phenotype 3 months after injection   (MGI Ref ID J:200783)
  • ovary degeneration
    • 2 of 7 mice injected with an adenovirus expressing cre recombinase into the bursa exhibit ovary degeneration 6 months after injection   (MGI Ref ID J:200783)
  • reproductive system phenotype
  • ovary cysts
    • 2 of 7 mice injected with an adenovirus expressing cre recombinase into the bursa develop bursal cysts 6 months after injection   (MGI Ref ID J:200783)
    • however, mice injected with an adenovirus expressing cre recombinase into the oviduct exhibit no change in phenotype 3 months after injection   (MGI Ref ID J:200783)
  • ovary degeneration
    • 2 of 7 mice injected with an adenovirus expressing cre recombinase into the bursa exhibit ovary degeneration 6 months after injection   (MGI Ref ID J:200783)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Trp53tm1Brn/Trp53+ Tg(MMTV-cre)4Mam/0

        involves: 129P2/OlaHsd * FVB   (conditional)
  • tumorigenesis
  • increased mammary gland tumor incidence
    • 92% of mice have mammary tumors   (MGI Ref ID J:170898)
    • many mice have tumors in more than one gland   (MGI Ref ID J:170898)
    • mammary tumors are either spindle/epithelial-mesenchymal transition or poorly differentiated adenocarcinoma   (MGI Ref ID J:170898)
    • increased mammary adenocarcinoma incidence   (MGI Ref ID J:170898)

Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)25Mes/0

        involves: 129P2/OlaHsd * C57BL/6 * FVB/N   (conditional)
  • tumorigenesis
  • increased astrocytoma incidence
    • 4 of 23 mice develop anaplastic astrocytomas   (MGI Ref ID J:140704)

Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0

        involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL   (conditional)
  • tumorigenesis
  • increased medulloblastoma incidence
    • 2/5 (40%) of mice receiving 4 Gy radiation at P5 develop cerebellar tumors by 5 months of age   (MGI Ref ID J:102702)

Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Trp53tm1Brn/Trp53+

        involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N   (conditional)
  • tumorigenesis
  • increased osteosarcoma incidence
    • low penetrance (8.33%) of osteosarcomas with a long latency of 338 days of age on average   (MGI Ref ID J:136693)

Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Trp53tm1Brn/Trp53tm1Brn

        involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N   (conditional)
  • mortality/aging
  • premature death
    • mice die from around 250 to 375 days of age   (MGI Ref ID J:136693)
  • tumorigenesis
  • increased metastatic potential
    • tumors show metastasis, most frequently to the lung and then the liver   (MGI Ref ID J:136693)
  • increased osteosarcoma incidence
    • complete penetrance of osteosarcomas with an average latency of 292 days   (MGI Ref ID J:136693)

Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Trp53tm1Brn/Trp53tm1Brn

        involves: 129P2/OlaHsd * C57BL/6 * CD-1   (conditional)
  • mortality/aging
  • premature death
    • mutants have a median survival of 226.5 days of age   (MGI Ref ID J:199542)
  • tumorigenesis
  • increased metastatic potential
    • 50% of mice show metastatic dissemination, commonly to the lung and liver   (MGI Ref ID J:199542)
  • increased osteosarcoma incidence
    • mutants develop osteosarcoma with a mean latency of 226.5 days   (MGI Ref ID J:199542)
    • 25% of tumors are found on the mandible/head, 50% of tumors are found on the lower long bones, and 25% of tumors are in other axial locations   (MGI Ref ID J:199542)
    • osteosarcoma is characterized by predominant areas of fibroblastic (undifferentiated) morphology accompanied by intermittent areas of mineralized osteoid resembling human fibroblastic/undifferentiated osteosarcoma   (MGI Ref ID J:199542)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Research Tools
Cancer Research
Cre-lox System
      loxP-flanked Sequences

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Trp53tm1Brn
Allele Name targeted mutation 1, Anton Berns
Allele Type Targeted (Conditional ready (e.g. floxed), No functional change)
Common Name(s) Tp53flx; Trp53F2-10; Trp53F2-F10; Trp53Fl; Trp53loxP; p53Co; p53F2-10; p53F2-10F; p53F; p53Fl; p53L; p53LoxP; p53flox; p53lox; p53Fl;
Mutation Made ByDr. Anton Berns,   University of Amsterdam
Strain of Origin129P2/OlaHsd
ES Cell Line NameIB10/E14IB10
ES Cell Line Strain129P2/OlaHsd
Gene Symbol and Name Trp53, transformation related protein 53
Chromosome 11
Gene Common Name(s) BCC7; LFS1; P53; p44;
General Note Phenotypic Similarity to Human Syndrome: Intrahepatic CholangiocarcinomaJ:184949.

Phenotypic Similarity to Human Syndrome: Soft Tissue Sarcoma J:125101 in double Kras and Trp53 mutants.

Phenotypic Similarity to Human Syndrome: Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma/Malignant Fibrous Histiocytoma J:155389, J:204376 in double Kras and Trp53 mutants.

Molecular Note Insertion of loxP sites flanking exons 2 through 10. No effect on the normal function of the gene. [MGI Ref ID J:61961]

Genotyping

Genotyping Information

Genotyping Protocols

Trp53tm1Brn, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Marino S; Vooijs M; van Der Gulden H; Jonkers J; Berns A. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14(8):994-1004. [PubMed: 10783170]  [MGI Ref ID J:61961]

Additional References

Trp53tm1Brn related

Abraham J; Chua YX; Glover JM; Tyner JW; Loriaux MM; Kilcoyne A; Giles FJ; Nelon LD; Carew JS; Ouyang Y; Michalek JE; Pal R; Druker BJ; Rubin BP; Keller C. 2012. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun 426(3):363-8. [PubMed: 22960170]  [MGI Ref ID J:190138]

Acin S; Li Z; Mejia O; Roop DR; El-Naggar AK; Caulin C. 2011. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 225(4):479-89. [PubMed: 21952947]  [MGI Ref ID J:177463]

Adams JR; Xu K; Liu JC; Agamez NM; Loch AJ; Wong RG; Wang W; Wright KL; Lane TF; Zacksenhaus E; Egan SE. 2011. Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation. Cancer Res 71(7):2706-2717. [PubMed: 21324922]  [MGI Ref ID J:170898]

Alvarez R; Musteanu M; Garcia-Garcia E; Lopez-Casas PP; Megias D; Guerra C; Munoz M; Quijano Y; Cubillo A; Rodriguez-Pascual J; Plaza C; de Vicente E; Prados S; Tabernero S; Barbacid M; Lopez-Rios F; Hidalgo M. 2013. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109(4):926-33. [PubMed: 23907428]  [MGI Ref ID J:208756]

Antico Arciuch VG; Russo MA; Dima M; Kang KS; Dasrath F; Liao XH; Refetoff S; Montagna C; Di Cristofano A. 2011. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget 2(12):1109-26. [PubMed: 22190384]  [MGI Ref ID J:211100]

Ardito CM; Gruner BM; Takeuchi KK; Lubeseder-Martellato C; Teichmann N; Mazur PK; Delgiorno KE; Carpenter ES; Halbrook CJ; Hall JC; Pal D; Briel T; Herner A; Trajkovic-Arsic M; Sipos B; Liou GY; Storz P; Murray NR; Threadgill DW; Sibilia M; Washington MK; Wilson CL; Schmid RM; Raines EW; Crawford HC; Siveke JT. 2012. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3):304-17. [PubMed: 22975374]  [MGI Ref ID J:190126]

Ayala de la Pena F; Kanasaki K; Kanasaki M; Tangirala N; Maeda G; Kalluri R. 2011. Loss of p53 and Acquisition of Angiogenic MicroRNA Profile Are Insufficient to Facilitate Progression of Bladder Urothelial Carcinoma in Situ to Invasive Carcinoma. J Biol Chem 286(23):20778-87. [PubMed: 21388952]  [MGI Ref ID J:173505]

Ayrault O; Godeny MD; Dillon C; Zindy F; Fitzgerald P; Roussel MF; Beere HM. 2009. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci U S A 106(40):17037-42. [PubMed: 19805107]  [MGI Ref ID J:153693]

Aytes A; Mitrofanova A; Lefebvre C; Alvarez MJ; Castillo-Martin M; Zheng T; Eastham JA; Gopalan A; Pienta KJ; Shen MM; Califano A; Abate-Shen C. 2014. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell 25(5):638-51. [PubMed: 24823640]  [MGI Ref ID J:210591]

Badea CT; Athreya KK; Espinosa G; Clark D; Ghafoori AP; Li Y; Kirsch DG; Johnson GA; Annapragada A; Ghaghada KB. 2012. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS One 7(4):e34496. [PubMed: 22485175]  [MGI Ref ID J:187115]

Bailey SL; Gurley KE; Hoon-Kim K; Kelly-Spratt KS; Kemp CJ. 2008. Tumor suppression by p53 in the absence of Atm. Mol Cancer Res 6(7):1185-92. [PubMed: 18583527]  [MGI Ref ID J:139874]

Bardeesy N; Aguirre AJ; Chu GC; Cheng KH; Lopez LV; Hezel AF; Feng B; Brennan C; Weissleder R; Mahmood U; Hanahan D; Redston MS; Chin L; Depinho RA. 2006. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 103(15):5947-52. [PubMed: 16585505]  [MGI Ref ID J:108298]

Basseres DS; Ebbs A; Levantini E; Baldwin AS. 2010. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 70(9):3537-46. [PubMed: 20406971]  [MGI Ref ID J:159456]

Bayne LJ; Beatty GL; Jhala N; Clark CE; Rhim AD; Stanger BZ; Vonderheide RH. 2012. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822-35. [PubMed: 22698406]  [MGI Ref ID J:189283]

Begus-Nahrmann Y; Lechel A; Obenauf AC; Nalapareddy K; Peit E; Hoffmann E; Schlaudraff F; Liss B; Schirmacher P; Kestler H; Danenberg E; Barker N; Clevers H; Speicher MR; Rudolph KL. 2009. p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice. Nat Genet 41(10):1138-43. [PubMed: 19718028]  [MGI Ref ID J:155011]

Berman SD; Calo E; Landman AS; Danielian PS; Miller ES; West JC; Fonhoue BD; Caron A; Bronson R; Bouxsein ML; Mukherjee S; Lees JA. 2008. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci U S A 105(33):11851-6. [PubMed: 18697945]  [MGI Ref ID J:139697]

Blum JM; Ano L; Li Z; Van Mater D; Bennett BD; Sachdeva M; Lagutina I; Zhang M; Mito JK; Dodd LG; Cardona DM; Dodd RD; Williams N; Ma Y; Lepper C; Linardic CM; Mukherjee S; Grosveld GC; Fan CM; Kirsch DG. 2013. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep 5(4):933-40. [PubMed: 24239359]  [MGI Ref ID J:205518]

Boumahdi S; Driessens G; Lapouge G; Rorive S; Nassar D; Le Mercier M; Delatte B; Caauwe A; Lenglez S; Nkusi E; Brohee S; Salmon I; Dubois C; del Marmol V; Fuks F; Beck B; Blanpain C. 2014. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511(7508):246-50. [PubMed: 24909994]  [MGI Ref ID J:213264]

Bowman-Colin C; Xia B; Bunting S; Klijn C; Drost R; Bouwman P; Fineman L; Chen X; Culhane AC; Cai H; Rodig SJ; Bronson RT; Jonkers J; Nussenzweig A; Kanellopoulou C; Livingston DM. 2013. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci U S A 110(21):8632-7. [PubMed: 23657012]  [MGI Ref ID J:197442]

Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM. 2014. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 509(7501):492-6. [PubMed: 24717435]  [MGI Ref ID J:210437]

Brennan RC; Federico S; Bradley C; Zhang J; Flores-Otero J; Wilson M; Stewart C; Zhu F; Guy K; Dyer MA. 2011. Targeting the p53 Pathway in Retinoblastoma with Subconjunctival Nutlin-3a. Cancer Res 71(12):4205-13. [PubMed: 21515735]  [MGI Ref ID J:173754]

Budanov AV; Karin M. 2008. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134(3):451-60. [PubMed: 18692468]  [MGI Ref ID J:139563]

Burd CE; Sorrentino JA; Clark KS; Darr DB; Krishnamurthy J; Deal AM; Bardeesy N; Castrillon DH; Beach DH; Sharpless NE. 2013. Monitoring tumorigenesis and senescence in vivo with a p16(INK4a)-luciferase model. Cell 152(1-2):340-51. [PubMed: 23332765]  [MGI Ref ID J:193498]

Burnum KE; Hirota Y; Baker ES; Yoshie M; Ibrahim YM; Monroe ME; Anderson GA; Smith RD; Daikoku T; Dey SK. 2012. Uterine deletion of Trp53 compromises antioxidant responses in the mouse decidua. Endocrinology 153(9):4568-79. [PubMed: 22759378]  [MGI Ref ID J:189180]

Calbo J; Meuwissen R; van Montfort E; van Tellingen O; Berns A. 2005. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol 70:225-32. [PubMed: 16869758]  [MGI Ref ID J:115156]

Calbo J; van Montfort E; Proost N; van Drunen E; Beverloo HB; Meuwissen R; Berns A. 2011. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell 19(2):244-56. [PubMed: 21316603]  [MGI Ref ID J:169448]

Calo E; Quintero-Estades JA; Danielian PS; Nedelcu S; Berman SD; Lees JA. 2010. Rb regulates fate choice and lineage commitment in vivo. Nature 466(7310):1110-4. [PubMed: 20686481]  [MGI Ref ID J:163313]

Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117(7):1893-901. [PubMed: 17607363]  [MGI Ref ID J:124222]

Cellurale C; Girnius N; Jiang F; Cavanagh-Kyros J; Lu S; Garlick DS; Mercurio AM; Davis RJ. 2012. Role of JNK in mammary gland development and breast cancer. Cancer Res 72(2):472-81. [PubMed: 22127926]  [MGI Ref ID J:181146]

Cellurale C; Sabio G; Kennedy NJ; Das M; Barlow M; Sandy P; Jacks T; Davis RJ. 2011. Requirement of c-Jun NH2-Terminal Kinase for Ras-Initiated Tumor Formation. Mol Cell Biol 31(7):1565-76. [PubMed: 21282468]  [MGI Ref ID J:170101]

Cha J; Bartos A; Egashira M; Haraguchi H; Saito-Fujita T; Leishman E; Bradshaw H; Dey SK; Hirota Y. 2013. Combinatory approaches prevent preterm birth profoundly exacerbated by gene-environment interactions. J Clin Invest 123(9):4063-75. [PubMed: 23979163]  [MGI Ref ID J:201582]

Chen Q; Khoury M; Chen J. 2009. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc Natl Acad Sci U S A :. [PubMed: 19966223]  [MGI Ref ID J:155817]

Chen YW; Klimstra DS; Mongeau ME; Tatem JL; Boyartchuk V; Lewis BC. 2007. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 67(16):7589-96. [PubMed: 17699762]  [MGI Ref ID J:124361]

Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Pena CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Janne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK. 2012. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483(7391):613-7. [PubMed: 22425996]  [MGI Ref ID J:182575]

Cheng L; Zhou Z; Flesken-Nikitin A; Toshkov IA; Wang W; Camps J; Ried T; Nikitin AY. 2010. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. Oncogene 29(42):5700-11. [PubMed: 20676140]  [MGI Ref ID J:165292]

Cheung AF; Dupage MJ; Dong HK; Chen J; Jacks T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 68(22):9459-68. [PubMed: 19010921]  [MGI Ref ID J:141383]

Chiche A; Moumen M; Petit V; Jonkers J; Medina D; Deugnier MA; Faraldo MM; Glukhova MA. 2013. Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal. Stem Cells 31(9):1857-67. [PubMed: 23712598]  [MGI Ref ID J:202727]

Cho H; Herzka T; Zheng W; Qi J; Wilkinson JE; Bradner JE; Robinson BD; Castillo-Martin M; Cordon-Cardo C; Trotman LC. 2014. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov 4(3):318-33. [PubMed: 24444712]  [MGI Ref ID J:211600]

Choi J; Curtis SJ; Roy DM; Flesken-Nikitin A; Nikitin AY. 2010. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol 177(5):2645-58. [PubMed: 20864684]  [MGI Ref ID J:166254]

Choi N; Zhang B; Zhang L; Ittmann M; Xin L. 2012. Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation. Cancer Cell 21(2):253-65. [PubMed: 22340597]  [MGI Ref ID J:181459]

Choi SH; Lee HJ; Jin YB; Jang J; Kang GY; Lee M; Kim CH; Kim J; Yoon SS; Lee YS; Lee YJ. 2014. MMP9 processing of HSPB1 regulates tumor progression. PLoS One 9(1):e85509. [PubMed: 24465581]  [MGI Ref ID J:212340]

Chow LM; Endersby R; Zhu X; Rankin S; Qu C; Zhang J; Broniscer A; Ellison DW; Baker SJ. 2011. Cooperativity within and among Pten, p53, and Rb Pathways Induces High-Grade Astrocytoma in Adult Brain. Cancer Cell 19(3):305-16. [PubMed: 21397855]  [MGI Ref ID J:169931]

Clark-Knowles KV; Garson K; Jonkers J; Vanderhyden BC. 2007. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 313(1):133-45. [PubMed: 17070800]  [MGI Ref ID J:117113]

Clark-Knowles KV; Senterman MK; Collins O; Vanderhyden BC. 2009. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 4(12):e8534. [PubMed: 20046869]  [MGI Ref ID J:155940]

Conkrite K; Sundby M; Mu D; Mukai S; MacPherson D. 2012. Cooperation between Rb and Arf in suppressing mouse retinoblastoma. J Clin Invest 122(5):1726-33. [PubMed: 22484813]  [MGI Ref ID J:184538]

Corcoran RB; Cheng KA; Hata AN; Faber AC; Ebi H; Coffee EM; Greninger P; Brown RD; Godfrey JT; Cohoon TJ; Song Y; Lifshits E; Hung KE; Shioda T; Dias-Santagata D; Singh A; Settleman J; Benes CH; Mino-Kenudson M; Wong KK; Engelman JA. 2013. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23(1):121-8. [PubMed: 23245996]  [MGI Ref ID J:194363]

Cui M; Augert A; Rongione M; Conkrite K; Parazzoli S; Nikitin AY; Ingolia N; Macpherson D. 2014. PTEN Is a Potent Suppressor of Small Cell Lung Cancer. Mol Cancer Res 12(5):654-9. [PubMed: 24482365]  [MGI Ref ID J:209151]

Curtis SJ; Sinkevicius KW; Li D; Lau AN; Roach RR; Zamponi R; Woolfenden AE; Kirsch DG; Wong KK; Kim CF. 2010. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 7(1):127-33. [PubMed: 20621056]  [MGI Ref ID J:162238]

Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK. 2008. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68(14):5619-27. [PubMed: 18632614]  [MGI Ref ID J:139053]

Daikoku T; Tranguch S; Trofimova IN; Dinulescu DM; Jacks T; Nikitin AY; Connolly DC; Dey SK. 2006. Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res 66(5):2527-31. [PubMed: 16510568]  [MGI Ref ID J:106703]

Dankort D; Filenova E; Collado M; Serrano M; Jones K; McMahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21(4):379-84. [PubMed: 17299132]  [MGI Ref ID J:121715]

De Raedt T; Walton Z; Yecies JL; Li D; Chen Y; Malone CF; Maertens O; Jeong SM; Bronson RT; Lebleu V; Kalluri R; Normant E; Haigis MC; Manning BD; Wong KK; Macleod KF; Cichowski K. 2011. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20(3):400-13. [PubMed: 21907929]  [MGI Ref ID J:175966]

Derksen PW; Braumuller TM; van der Burg E; Hornsveld M; Mesman E; Wesseling J; Krimpenfort P; Jonkers J. 2011. Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 4(3):347-58. [PubMed: 21282721]  [MGI Ref ID J:171765]

Derksen PW; Liu X; Saridin F; van der Gulden H; Zevenhoven J; Evers B; van Beijnum JR; Griffioen AW; Vink J; Krimpenfort P; Peterse JL; Cardiff RD; Berns A; Jonkers J. 2006. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10(5):437-49. [PubMed: 17097565]  [MGI Ref ID J:116152]

Ding Z; Wu CJ; Jaskelioff M; Ivanova E; Kost-Alimova M; Protopopov A; Chu GC; Wang G; Lu X; Labrot ES; Hu J; Wang W; Xiao Y; Zhang H; Zhang J; Zhang J; Gan B; Perry SR; Jiang S; Li L; Horner JW; Wang YA; Chin L; DePinho RA. 2012. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148(5):896-907. [PubMed: 22341455]  [MGI Ref ID J:186105]

Dooley AL; Winslow MM; Chiang DY; Banerji S; Stransky N; Dayton TL; Snyder EL; Senna S; Whittaker CA; Bronson RT; Crowley D; Barretina J; Garraway L; Meyerson M; Jacks T. 2011. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 25(14):1470-5. [PubMed: 21764851]  [MGI Ref ID J:174756]

Doornebal CW; Klarenbeek S; Braumuller TM; Klijn CN; Ciampricotti M; Hau CS; Hollmann MW; Jonkers J; de Visser KE. 2013. A preclinical mouse model of invasive lobular breast cancer metastasis. Cancer Res 73(1):353-63. [PubMed: 23151903]  [MGI Ref ID J:194100]

Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ. 2010. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 222(2):129-37. [PubMed: 20662002]  [MGI Ref ID J:163599]

Drost R; Bouwman P; Rottenberg S; Boon U; Schut E; Klarenbeek S; Klijn C; van der Heijden I; van der Gulden H; Wientjens E; Pieterse M; Catteau A; Green P; Solomon E; Morris JR; Jonkers J. 2011. BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance. Cancer Cell 20(6):797-809. [PubMed: 22172724]  [MGI Ref ID J:178595]

DuPage M; Dooley AL; Jacks T. 2009. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064-72. [PubMed: 19561589]  [MGI Ref ID J:201034]

DuPage M; Mazumdar C; Schmidt LM; Cheung AF; Jacks T. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482(7385):405-9. [PubMed: 22318517]  [MGI Ref ID J:181323]

Dupage M; Cheung AF; Mazumdar C; Winslow MM; Bronson R; Schmidt LM; Crowley D; Chen J; Jacks T. 2011. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19(1):72-85. [PubMed: 21251614]  [MGI Ref ID J:168066]

Eisinger-Mathason TS; Zhang M; Qiu Q; Skuli N; Nakazawa MS; Karakasheva T; Mucaj V; Shay JE; Stangenberg L; Sadri N; Pure E; Yoon SS; Kirsch DG; Simon MC. 2013. Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov 3(10):1190-205. [PubMed: 23906982]  [MGI Ref ID J:204376]

Elyada E; Pribluda A; Goldstein RE; Morgenstern Y; Brachya G; Cojocaru G; Snir-Alkalay I; Burstain I; Haffner-Krausz R; Jung S; Wiener Z; Alitalo K; Oren M; Pikarsky E; Ben-Neriah Y. 2011. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 470(7334):409-13. [PubMed: 21331045]  [MGI Ref ID J:204886]

Eser S; Reiff N; Messer M; Seidler B; Gottschalk K; Dobler M; Hieber M; Arbeiter A; Klein S; Kong B; Michalski CW; Schlitter AM; Esposito I; Kind AJ; Rad L; Schnieke AE; Baccarini M; Alessi DR; Rad R; Schmid RM; Schneider G; Saur D. 2013. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23(3):406-20. [PubMed: 23453624]  [MGI Ref ID J:197054]

Evers B; Speksnijder EN; Schut E; Ciampricotti M; Smalley MJ; Derksen PW; Jonkers J; de Visser KE. 2010. A tissue reconstitution model to study cancer cell-intrinsic and -extrinsic factors in mammary tumourigenesis. J Pathol 220(1):34-44. [PubMed: 19927317]  [MGI Ref ID J:155546]

Feridooni T; Hotchkiss A; Remley-Carr S; Saga Y; Pasumarthi KB. 2011. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One 6(7):e22801. [PubMed: 21829519]  [MGI Ref ID J:175833]

Fishler T; Li YY; Wang RH; Kim HS; Sengupta K; Vassilopoulos A; Lahusen T; Xu X; Lee MH; Liu Q; Elledge SJ; Ried T; Deng CX. 2010. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29(28):4007-17. [PubMed: 20473325]  [MGI Ref ID J:162126]

Flesken-Nikitin A; Choi KC; Eng JP; Shmidt EN; Nikitin AY. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63(13):3459-63. [PubMed: 12839925]  [MGI Ref ID J:84345]

Flesken-Nikitin A; Hwang CI; Cheng CY; Michurina TV; Enikolopov G; Nikitin AY. 2013. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 495(7440):241-5. [PubMed: 23467088]  [MGI Ref ID J:194916]

Forsberg K; Wuttke A; Quadrato G; Chumakov PM; Wizenmann A; Di Giovanni S. 2013. The tumor suppressor p53 fine-tunes reactive oxygen species levels and neurogenesis via PI3 kinase signaling. J Neurosci 33(36):14318-30. [PubMed: 24005285]  [MGI Ref ID J:201646]

Forys JT; Kuzmicki CE; Saporita AJ; Winkeler CL; Maggi LB Jr; Weber JD. 2014. ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-ISG15 signaling axis. Cell Rep 7(2):514-26. [PubMed: 24726362]  [MGI Ref ID J:211814]

Francis JC; McCarthy A; Thomsen MK; Ashworth A; Swain A. 2010. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 6(6):e1000995. [PubMed: 20585617]  [MGI Ref ID J:161511]

Fukuda A; Wang SC; Morris JP 4th; Folias AE; Liou A; Kim GE; Akira S; Boucher KM; Firpo MA; Mulvihill SJ; Hebrok M. 2011. Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell 19(4):441-55. [PubMed: 21481787]  [MGI Ref ID J:170982]

Gao Y; Xiao Q; Ma H; Li L; Liu J; Feng Y; Fang Z; Wu J; Han X; Zhang J; Sun Y; Wu G; Padera R; Chen H; Wong KK; Ge G; Ji H. 2010. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 107(44):18892-7. [PubMed: 20956321]  [MGI Ref ID J:166159]

Genovese G; Ergun A; Shukla SA; Campos B; Hanna J; Ghosh P; Quayle SN; Rai K; Colla S; Ying H; Wu CJ; Sarkar S; Xiao Y; Zhang J; Zhang H; Kwong L; Dunn K; Wiedemeyer WR; Brennan C; Zheng H; Rimm DL; Collins JJ; Chin L. 2012. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-beta signaling in glioblastoma. Cancer Discov 2(8):736-49. [PubMed: 22750848]  [MGI Ref ID J:193159]

Gibson P; Tong Y; Robinson G; Thompson MC; Currle DS; Eden C; Kranenburg TA; Hogg T; Poppleton H; Martin J; Finkelstein D; Pounds S; Weiss A; Patay Z; Scoggins M; Ogg R; Pei Y; Yang ZJ; Brun S; Lee Y; Zindy F; Lindsey JC; Taketo MM; Boop FA; Sanford RA; Gajjar A; Clifford SC; Roussel MF; McKinnon PJ; Gutmann DH; Ellison DW; Wechsler-Reya R; Gilbertson RJ. 2010. Subtypes of medulloblastoma have distinct developmental origins. Nature 468(7327):1095-9. [PubMed: 21150899]  [MGI Ref ID J:167212]

Gidekel Friedlander SY; Chu GC; Snyder EL; Girnius N; Dibelius G; Crowley D; Vasile E; DePinho RA; Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 16(5):379-89. [PubMed: 19878870]  [MGI Ref ID J:153948]

Gil-Perotin S; Marin-Husstege M; Li J; Soriano-Navarro M; Zindy F; Roussel MF; Garcia-Verdugo JM; Casaccia-Bonnefil P. 2006. Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. J Neurosci 26(4):1107-16. [PubMed: 16436596]  [MGI Ref ID J:104815]

Goh AM; Lim CY; Chiam PC; Li L; Mann MB; Mann KM; Menendez S; Lane DP. 2012. Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity. Proc Natl Acad Sci U S A 109(5):1685-90. [PubMed: 22307631]  [MGI Ref ID J:182031]

Gore AJ; Deitz SL; Palam LR; Craven KE; Korc M. 2014. Pancreatic cancer-associated retinoblastoma 1 dysfunction enables TGF-beta to promote proliferation. J Clin Invest 124(1):338-52. [PubMed: 24334458]  [MGI Ref ID J:207615]

Gostissa M; Bianco JM; Malkin DJ; Kutok JL; Rodig SJ; Morse HC 3rd; Bassing CH; Alt FW. 2013. Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas. Proc Natl Acad Sci U S A 110(8):2934-9. [PubMed: 23382223]  [MGI Ref ID J:194540]

Greenow KR; Clarke AR; Jones RH. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28(11):1443-53. [PubMed: 19169280]  [MGI Ref ID J:147589]

Grim JE; Knoblaugh SE; Guthrie KA; Hagar A; Swanger J; Hespelt J; Delrow JJ; Small T; Grady WM; Nakayama KI; Clurman BE. 2012. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. Mol Cell Biol 32(11):2160-7. [PubMed: 22473991]  [MGI Ref ID J:185723]

Guerra C; Collado M; Navas C; Schuhmacher AJ; Hernandez-Porras I; Canamero M; Rodriguez-Justo M; Serrano M; Barbacid M. 2011. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19(6):728-39. [PubMed: 21665147]  [MGI Ref ID J:173561]

Guest RV; Boulter L; Kendall TJ; Minnis-Lyons SE; Walker R; Wigmore SJ; Sansom OJ; Forbes SJ. 2014. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res 74(4):1005-10. [PubMed: 24310400]  [MGI Ref ID J:206969]

Guinea-Viniegra J; Zenz R; Scheuch H; Jimenez M; Bakiri L; Petzelbauer P; Wagner EF. 2012. Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J Clin Invest 122(8):2898-910. [PubMed: 22772468]  [MGI Ref ID J:190075]

Guo JY; Karsli-Uzunbas G; Mathew R; Aisner SC; Kamphorst JJ; Strohecker AM; Chen G; Price S; Lu W; Teng X; Snyder E; Santanam U; Dipaola RS; Jacks T; Rabinowitz JD; White E. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 27(13):1447-61. [PubMed: 23824538]  [MGI Ref ID J:199455]

Hakem A; El Ghamrasni S; Maire G; Lemmers B; Karaskova J; Jurisicova A; Sanchez O; Squire J; Hakem R. 2012. Caspase-8 is essential for maintaining chromosomal stability and suppressing B-cell lymphomagenesis. Blood 119(15):3495-502. [PubMed: 22343728]  [MGI Ref ID J:183787]

Hammoud Z; Tan B; Badve S; Bigsby RM. 2008. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15(2):475-83. [PubMed: 18509000]  [MGI Ref ID J:149009]

Han X; Li F; Fang Z; Gao Y; Li F; Fang R; Yao S; Sun Y; Li L; Zhang W; Ma H; Xiao Q; Ge G; Fang J; Wang H; Zhang L; Wong KK; Chen H; Hou Y; Ji H. 2014. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun 5:3261. [PubMed: 24531128]  [MGI Ref ID J:206810]

Hao Z; Duncan GS; Su YW; Li WY; Silvester J; Hong C; You H; Brenner D; Gorrini C; Haight J; Wakeham A; You-Ten A; McCracken S; Elia A; Li Q; Detmar J; Jurisicova A; Hobeika E; Reth M; Sheng Y; Lang PA; Ohashi PS; Zhong Q; Wang X; Mak TW. 2012. The E3 ubiquitin ligase Mule acts through the ATM-p53 axis to maintain B lymphocyte homeostasis. J Exp Med 209(1):173-86. [PubMed: 22213803]  [MGI Ref ID J:181705]

Hasselblatt P; Rath M; Komnenovic V; Zatloukal K; Wagner EF. 2007. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 104(43):17105-10. [PubMed: 17940019]  [MGI Ref ID J:125913]

Hay T; Matthews JR; Pietzka L; Lau A; Cranston A; Nygren AO; Douglas-Jones A; Smith GC; Martin NM; O'Connor M; Clarke AR. 2009. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 69(9):3850-5. [PubMed: 19383921]  [MGI Ref ID J:148266]

Hegde GV; de la Cruz CC; Chiu C; Alag N; Schaefer G; Crocker L; Ross S; Goldenberg D; Merchant M; Tien J; Shao L; Roth L; Tsai SP; Stawicki S; Jin Z; Wyatt SK; Carano RA; Zheng Y; Sweet-Cordero EA; Wu Y; Jackson EL. 2013. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 5(171):171ra18. [PubMed: 23390248]  [MGI Ref ID J:194531]

Henriquez NV; Forshew T; Tatevossian R; Ellis M; Richard-Loendt A; Rogers H; Jacques TS; Reitboeck PG; Pearce K; Sheer D; Grundy RG; Brandner S. 2013. Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro. Cancer Res 73(18):5834-44. [PubMed: 23887970]  [MGI Ref ID J:204385]

Hilliard SA; Yao X; El-Dahr SS. 2014. Mdm2 is required for maintenance of the nephrogenic niche. Dev Biol 387(1):1-14. [PubMed: 24440154]  [MGI Ref ID J:207609]

Hinkal G; Parikh N; Donehower LA. 2009. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 4(8):e6654. [PubMed: 19680549]  [MGI Ref ID J:152463]

Hirota Y; Cha J; Yoshie M; Daikoku T; Dey SK. 2011. Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice. Proc Natl Acad Sci U S A 108(44):18073-8. [PubMed: 22025690]  [MGI Ref ID J:180261]

Hirota Y; Daikoku T; Tranguch S; Xie H; Bradshaw HB; Dey SK. 2010. Uterine-specific p53 deficiency confers premature uterine senescence and promotes preterm birth in mice. J Clin Invest 120(3):803-15. [PubMed: 20124728]  [MGI Ref ID J:158498]

Hu J; Ho AL; Yuan L; Hu B; Hua S; Hwang SS; Zhang J; Hu T; Zheng H; Gan B; Wu G; Wang YA; Chin L; Depinho RA. 2013. From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci U S A 110(36):14520-7. [PubMed: 23918370]  [MGI Ref ID J:200674]

Huang YY; Dai L; Gaines D; Droz-Rosario R; Lu H; Liu J; Shen Z. 2013. BCCIP suppresses tumor initiation but is required for tumor progression. Cancer Res 73(23):7122-33. [PubMed: 24145349]  [MGI Ref ID J:206526]

Huijbers IJ; Bin Ali R; Pritchard C; Cozijnsen M; Kwon MC; Proost N; Song JY; de Vries H; Badhai J; Sutherland K; Krimpenfort P; Michalak EM; Jonkers J; Berns A. 2014. Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med 6(2):212-25. [PubMed: 24401838]  [MGI Ref ID J:210103]

Huo Y; Cai H; Teplova I; Bowman-Colin C; Chen G; Price S; Barnard N; Ganesan S; Karantza V; White E; Xia B. 2013. Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov 3(8):894-907. [PubMed: 23650262]  [MGI Ref ID J:203561]

Hwang CI; Matoso A; Corney DC; Flesken-Nikitin A; Korner S; Wang W; Boccaccio C; Thorgeirsson SS; Comoglio PM; Hermeking H; Nikitin AY. 2011. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A 108(34):14240-5. [PubMed: 21831840]  [MGI Ref ID J:175978]

Inoue S; Hao Z; Elia AJ; Cescon D; Zhou L; Silvester J; Snow B; Harris IS; Sasaki M; Li WY; Itsumi M; Yamamoto K; Ueda T; Dominguez-Brauer C; Gorrini C; Chio II; Haight J; You-Ten A; McCracken S; Wakeham A; Ghazarian D; Penn LJ; Melino G; Mak TW. 2013. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev 27(10):1101-14. [PubMed: 23699408]  [MGI Ref ID J:199183]

Issaeva N; Thomas HD; Djurenovic T; Jaspers JE; Stoimenov I; Kyle S; Pedley N; Gottipati P; Zur R; Sleeth K; Chatzakos V; Mulligan EA; Lundin C; Gubanova E; Kersbergen A; Harris AL; Sharma RA; Rottenberg S; Curtin NJ; Helleday T. 2010. 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. Cancer Res 70(15):6268-6276. [PubMed: 20631063]  [MGI Ref ID J:162234]

Ittmann M; Huang J; Radaelli E; Martin P; Signoretti S; Sullivan R; Simons BW; Ward JM; Robinson BD; Chu GC; Loda M; Thomas G; Borowsky A; Cardiff RD. 2013. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73(9):2718-36. [PubMed: 23610450]  [MGI Ref ID J:197036]

Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65(22):10280-8. [PubMed: 16288016]  [MGI Ref ID J:103407]

Jacques TS; Swales A; Brzozowski MJ; Henriquez NV; Linehan JM; Mirzadeh Z; O' Malley C; Naumann H; Alvarez-Buylla A; Brandner S. 2010. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J 29(1):222-35. [PubMed: 19927122]  [MGI Ref ID J:156395]

Jahchan NS; Dudley JT; Mazur PK; Flores N; Yang D; Palmerton A; Zmoos AF; Vaka D; Tran KQ; Zhou M; Krasinska K; Riess JW; Neal JW; Khatri P; Park KS; Butte AJ; Sage J. 2013. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3(12):1364-77. [PubMed: 24078773]  [MGI Ref ID J:208199]

Jameson KL; Mazur PK; Zehnder AM; Zhang J; Zarnegar B; Sage J; Khavari PA. 2013. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 19(5):626-30. [PubMed: 23603816]  [MGI Ref ID J:198505]

Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S. 2013. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3(1):68-81. [PubMed: 23103855]  [MGI Ref ID J:193631]

Ji H; Ramsey MR; Hayes DN; Fan C; McNamara K; Kozlowski P; Torrice C; Wu MC; Shimamura T; Perera SA; Liang MC; Cai D; Naumov GN; Bao L; Contreras CM; Li D; Chen L; Krishnamurthy J; Koivunen J; Chirieac LR; Padera RF; Bronson RT; Lindeman NI; Christiani DC; Lin X; Shapiro GI; Janne PA; Johnson BE; Meyerson M; Kwiatkowski DJ; Castrillon DH; Bardeesy N; Sharpless NE; Wong KK. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807-10. [PubMed: 17676035]  [MGI Ref ID J:124682]

Johnson DA; Zhang J; Frase S; Wilson M; Rodriguez-Galindo C; Dyer MA. 2007. Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res 67(6):2701-11. [PubMed: 17363591]  [MGI Ref ID J:120315]

Jongsma J; van Montfort E; Vooijs M; Zevenhoven J; Krimpenfort P; van der Valk M; van de Vijver M; Berns A. 2008. A conditional mouse model for malignant mesothelioma. Cancer Cell 13(3):261-71. [PubMed: 18328429]  [MGI Ref ID J:132943]

Jonkers J; Meuwissen R; van Der Gulden H; Peterse H; van Der Valk M; Berns A. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29(4):418-25. [PubMed: 11694875]  [MGI Ref ID J:73028]

Jurado S; Gleeson K; O'Donnell K; Izon DJ; Walkley CR; Strasser A; Tarlinton DM; Heierhorst J. 2012. The Zinc-finger protein ASCIZ regulates B cell development via DYNLL1 and Bim. J Exp Med 209(9):1629-39. [PubMed: 22891272]  [MGI Ref ID J:191832]

Kalamarides M; Stemmer-Rachamimov AO; Niwa-Kawakita M; Chareyre F; Taranchon E; Han ZY; Martinelli C; Lusis EA; Hegedus B; Gutmann DH; Giovannini M. 2011. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 30(20):2333-44. [PubMed: 21242963]  [MGI Ref ID J:173718]

Kawashima H; Takatori H; Suzuki K; Iwata A; Yokota M; Suto A; Minamino T; Hirose K; Nakajima H. 2013. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J Immunol 191(7):3614-23. [PubMed: 24006461]  [MGI Ref ID J:205943]

Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF. 2012. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell 21(2):168-80. [PubMed: 22340591]  [MGI Ref ID J:181462]

Kazarian M; Calbo J; Proost N; Carpenter CL; Berns A; Laird-Offringa IA. 2009. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol 217(1-2):38-45. [PubMed: 19765830]  [MGI Ref ID J:157319]

Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR. 2004. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18(21):2614-26. [PubMed: 15489287]  [MGI Ref ID J:93444]

Kikuchi K; Hettmer S; Aslam MI; Michalek JE; Laub W; Wilky BA; Loeb DM; Rubin BP; Wagers AJ; Keller C. 2014. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet 10(1):e1004107. [PubMed: 24453992]  [MGI Ref ID J:208787]

Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH Jr; Beachy PA; Rudin CM. 2013. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23(1):23-34. [PubMed: 23291299]  [MGI Ref ID J:194353]

Kim J; Roh M; Doubinskaia I; Algarroba GN; Eltoum IE; Abdulkadir SA. 2012. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 31(3):322-32. [PubMed: 21685943]  [MGI Ref ID J:181074]

Kim J; Tang JY; Gong R; Kim J; Lee JJ; Clemons KV; Chong CR; Chang KS; Fereshteh M; Gardner D; Reya T; Liu JO; Epstein EH; Stevens DA; Beachy PA. 2010. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17(4):388-99. [PubMed: 20385363]  [MGI Ref ID J:158946]

Kim KY; Park DW; Jeung EB; Choi KC. 2010. Conditional knockout of brca1/2 and p53 in mouse ovarian surface epithelium: do they play a role in ovarian carcinogenesis? J Vet Sci 11(4):291-7. [PubMed: 21113097]  [MGI Ref ID J:168730]

Kinsey C; Balakrishnan V; O'Dell MR; Huang JL; Newman L; Whitney-Miller CL; Hezel AF; Land H. 2014. Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. Cell Rep 7(4):1143-55. [PubMed: 24794439]  [MGI Ref ID J:211801]

Kirsch DG; Dinulescu DM; Miller JB; Grimm J; Santiago PM; Young NP; Nielsen GP; Quade BJ; Chaber CJ; Schultz CP; Takeuchi O; Bronson RT; Crowley D; Korsmeyer SJ; Yoon SS; Hornicek FJ; Weissleder R; Jacks T. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13(8):992-7. [PubMed: 17676052]  [MGI Ref ID J:125101]

Kirsch DG; Santiago PM; di Tomaso E; Sullivan JM; Hou WS; Dayton T; Jeffords LB; Sodha P; Mercer KL; Cohen R; Takeuchi O; Korsmeyer SJ; Bronson RT; Kim CF; Haigis KM; Jain RK; Jacks T. 2010. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327(5965):593-6. [PubMed: 20019247]  [MGI Ref ID J:156707]

Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M. 2013. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A 110(14):E1301-10. [PubMed: 23509284]  [MGI Ref ID J:194230]

Kodama T; Takehara T; Hikita H; Shimizu S; Shigekawa M; Tsunematsu H; Li W; Miyagi T; Hosui A; Tatsumi T; Ishida H; Kanto T; Hiramatsu N; Kubota S; Takigawa M; Tomimaru Y; Tomokuni A; Nagano H; Doki Y; Mori M; Hayashi N. 2011. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest 121(8):3343-56. [PubMed: 21747166]  [MGI Ref ID J:176163]

Koren S; Bentires-Alj M. 2013. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. FEBS J 280(12):2758-65. [PubMed: 23384338]  [MGI Ref ID J:213102]

Krimpenfort P; Song JY; Proost N; Zevenhoven J; Jonkers J; Berns A. 2012. Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 482(7386):538-41. [PubMed: 22358843]  [MGI Ref ID J:181090]

Kumar MS; Pester RE; Chen CY; Lane K; Chin C; Lu J; Kirsch DG; Golub TR; Jacks T. 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23(23):2700-4. [PubMed: 19903759]  [MGI Ref ID J:154907]

Kumar P; Mukherjee M; Johnson JP; Patel M; Huey B; Albertson DG; Simin K. 2012. Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution. PLoS Genet 8(11):e1003027. [PubMed: 23173005]  [MGI Ref ID J:194081]

Lapouge G; Youssef KK; Vokaer B; Achouri Y; Michaux C; Sotiropoulou PA; Blanpain C. 2011. Identifying the cellular origin of squamous skin tumors. Proc Natl Acad Sci U S A 108(18):7431-6. [PubMed: 21502497]  [MGI Ref ID J:172048]

Laurie N; Mohan A; McEvoy J; Reed D; Zhang J; Schweers B; Ajioka I; Valentine V; Johnson D; Ellison D; Dyer MA. 2009. Changes in retinoblastoma cell adhesion associated with optic nerve invasion. Mol Cell Biol 29(23):6268-82. [PubMed: 19786571]  [MGI Ref ID J:154999]

Laurie NA; Donovan SL; Shih CS; Zhang J; Mills N; Fuller C; Teunisse A; Lam S; Ramos Y; Mohan A; Johnson D; Wilson M; Rodriguez-Galindo C; Quarto M; Francoz S; Mendrysa SM; Guy RK; Marine JC; Jochemsen AG; Dyer MA. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444(7115):61-6. [PubMed: 17080083]  [MGI Ref ID J:115580]

Lechel A; Holstege H; Begus Y; Schienke A; Kamino K; Lehmann U; Kubicka S; Schirmacher P; Jonkers J; Rudolph KL. 2007. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 132(4):1465-75. [PubMed: 17433324]  [MGI Ref ID J:128326]

Lee JJ; Perera RM; Wang H; Wu DC; Liu XS; Han S; Fitamant J; Jones PD; Ghanta KS; Kawano S; Nagle JM; Deshpande V; Boucher Y; Kato T; Chen JK; Willmann JK; Bardeesy N; Beachy PA. 2014. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A 111(30):E3091-100. [PubMed: 25024225]  [MGI Ref ID J:212242]

Lee MN; Roy M; Ong SE; Mertins P; Villani AC; Li W; Dotiwala F; Sen J; Doench JG; Orzalli MH; Kramnik I; Knipe DM; Lieberman J; Carr SA; Hacohen N. 2012. Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol 14(2):179-85. [PubMed: 23263557]  [MGI Ref ID J:192611]

Li CM; Chen G; Dayton TL; Kim-Kiselak C; Hoersch S; Whittaker CA; Bronson RT; Beer DG; Winslow MM; Jacks T. 2013. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev 27(14):1557-67. [PubMed: 23873940]  [MGI Ref ID J:199363]

Li G; Kikuchi K; Radka M; Abraham J; Rubin BP; Keller C. 2013. IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment. Stem Cells 31(11):2304-12. [PubMed: 23897781]  [MGI Ref ID J:204014]

Li L; Hanahan D. 2013. Hijacking the neuronal NMDAR signaling circuit to promote tumor growth and invasion. Cell 153(1):86-100. [PubMed: 23540692]  [MGI Ref ID J:197249]

Lin C; Song H; Huang C; Yao E; Gacayan R; Xu SM; Chuang PT. 2012. Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One 7(12):e53817. [PubMed: 23285300]  [MGI Ref ID J:195738]

Lin PP; Pandey MK; Jin F; Raymond AK; Akiyama H; Lozano G. 2009. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 30(10):1789-95. [PubMed: 19635748]  [MGI Ref ID J:153430]

Lin PP; Pandey MK; Jin F; Xiong S; Deavers M; Parant JM; Lozano G. 2008. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 68(21):8968-75. [PubMed: 18974141]  [MGI Ref ID J:140636]

Linnoila RI; Naizhen X; Meuwissen R; Berns A; DeMayo FJ. 2005. Mouse lung neuroendocrine carcinomas: distinct morphologies, same transcription factors. Exp Lung Res 31(1):37-55. [PubMed: 15765918]  [MGI Ref ID J:97849]

Liu W; Monahan KB; Pfefferle AD; Shimamura T; Sorrentino J; Chan KT; Roadcap DW; Ollila DW; Thomas NE; Castrillon DH; Miller CR; Perou CM; Wong KK; Bear JE; Sharpless NE. 2012. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell 21(6):751-64. [PubMed: 22698401]  [MGI Ref ID J:189285]

Liu X; Holstege H; van der Gulden H; Treur-Mulder M; Zevenhoven J; Velds A; Kerkhoven RM; van Vliet MH; Wessels LF; Peterse JL; Berns A; Jonkers J. 2007. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A 104(29):12111-6. [PubMed: 17626182]  [MGI Ref ID J:126551]

Liu Y; Marks K; Cowley GS; Carretero J; Liu Q; Nieland TJ; Xu C; Cohoon TJ; Gao P; Zhang Y; Chen Z; Altabef AB; Tchaicha JH; Wang X; Choe S; Driggers EM; Zhang J; Bailey ST; Sharpless NE; Hayes DN; Patel NM; Janne PA; Bardeesy N; Engelman JA; Manning BD;Shaw RJ; Asara JM; Scully R; Kimmelman A; Byers LA; Gibbons DL; Wistuba II; Heymach JV; Kwiatkowski DJ; Kim WY; Kung AL; Gray NS; Root DE; Cantley LC; Wong KK. 2013. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 3(8):870-9. [PubMed: 23715154]  [MGI Ref ID J:203634]

Lucas D; Scheiermann C; Chow A; Kunisaki Y; Bruns I; Barrick C; Tessarollo L; Frenette PS. 2013. Chemotherapy-induced bone marrow nerve injury impairs hematopoietic regeneration. Nat Med 19(6):695-703. [PubMed: 23644514]  [MGI Ref ID J:198559]

Lujambio A; Akkari L; Simon J; Grace D; Tschaharganeh DF; Bolden JE; Zhao Z; Thapar V; Joyce JA; Krizhanovsky V; Lowe SW. 2013. Non-cell-autonomous tumor suppression by p53. Cell 153(2):449-60. [PubMed: 23562644]  [MGI Ref ID J:197241]

Marino S; Hoogervoorst D; Brandner S; Berns A. 2003. Rb and p107 are required for normal cerebellar development and granule cell survival but not for Purkinje cell persistence. Development 130(15):3359-68. [PubMed: 12810584]  [MGI Ref ID J:83783]

Marthiens V; Rujano MA; Pennetier C; Tessier S; Paul-Gilloteaux P; Basto R. 2013. Centrosome amplification causes microcephaly. Nat Cell Biol 15(7):731-40. [PubMed: 23666084]  [MGI Ref ID J:198922]

Martin P; Liu YN; Pierce R; Abou-Kheir W; Casey O; Seng V; Camacho D; Simpson RM; Kelly K. 2011. Prostate Epithelial Pten/TP53 Loss Leads to Transformation of Multipotential Progenitors and Epithelial to Mesenchymal Transition. Am J Pathol 179(1):422-35. [PubMed: 21703421]  [MGI Ref ID J:173998]

Martinez-Cruz AB; Santos M; Garcia-Escudero R; Moral M; Segrelles C; Lorz C; Saiz C; Buitrago-Perez A; Costa C; Paramio JM. 2009. Spontaneous tumor formation in Trp53-deficient epidermis mediated by chromosomal instability and inflammation. Anticancer Res 29(8):3035-42. [PubMed: 19661312]  [MGI Ref ID J:209263]

Martinez-Cruz AB; Santos M; Lara MF; Segrelles C; Ruiz S; Moral M; Lorz C; Garcia-Escudero R; Paramio JM. 2008. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68(3):683-92. [PubMed: 18245467]  [MGI Ref ID J:131867]

Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O. 2014. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510(7504):283-7. [PubMed: 24847881]  [MGI Ref ID J:213209]

McEvoy J; Flores-Otero J; Zhang J; Nemeth K; Brennan R; Bradley C; Krafcik F; Rodriguez-Galindo C; Wilson M; Xiong S; Lozano G; Sage J; Fu L; Louhibi L; Trimarchi J; Pani A; Smeyne R; Johnson D; Dyer MA. 2011. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20(2):260-75. [PubMed: 21840489]  [MGI Ref ID J:176061]

McFadden DG; Papagiannakopoulos T; Taylor-Weiner A; Stewart C; Carter SL; Cibulskis K; Bhutkar A; McKenna A; Dooley A; Vernon A; Sougnez C; Malstrom S; Heimann M; Park J; Chen F; Farago AF; Dayton T; Shefler E; Gabriel S; Getz G; Jacks T. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156(6):1298-311. [PubMed: 24630729]  [MGI Ref ID J:211996]

McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T. 2014. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A 111(16):E1600-9. [PubMed: 24711431]  [MGI Ref ID J:208854]

Mehta S; Huillard E; Kesari S; Maire CL; Golebiowski D; Harrington EP; Alberta JA; Kane MF; Theisen M; Ligon KL; Rowitch DH; Stiles CD. 2011. The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma. Cancer Cell 19(3):359-71. [PubMed: 21397859]  [MGI Ref ID J:169930]

Melchor L; Molyneux G; Mackay A; Magnay FA; Atienza M; Kendrick H; Nava-Rodrigues D; Lopez-Garcia MA; Milanezi F; Greenow K; Robertson D; Palacios J; Reis-Filho JS; Smalley MJ. 2014. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol 233(2):124-37. [PubMed: 24615332]  [MGI Ref ID J:210989]

Meuwissen R; Linn SC; Linnoila RI; Zevenhoven J; Mooi WJ; Berns A. 2003. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4(3):181-9. [PubMed: 14522252]  [MGI Ref ID J:86077]

Meylan E; Dooley AL; Feldser DM; Shen L; Turk E; Ouyang C; Jacks T. 2009. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462(7269):104-7. [PubMed: 19847165]  [MGI Ref ID J:154041]

Minamino T; Orimo M; Shimizu I; Kunieda T; Yokoyama M; Ito T; Nojima A; Nabetani A; Oike Y; Matsubara H; Ishikawa F; Komuro I. 2009. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med 15(9):1082-7. [PubMed: 19718037]  [MGI Ref ID J:154323]

Mito JK; Riedel RF; Dodd L; Lahat G; Lazar AJ; Dodd RD; Stangenberg L; Eward WC; Hornicek FJ; Yoon SS; Brigman BE; Jacks T; Lev D; Mukherjee S; Kirsch DG. 2009. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One 4(11):e8075. [PubMed: 19956606]  [MGI Ref ID J:155389]

Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J. 2013. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 3(5):548-63. [PubMed: 23454899]  [MGI Ref ID J:200122]

Monahan KB; Rozenberg GI; Krishnamurthy J; Johnson SM; Liu W; Bradford MK; Horner J; Depinho RA; Sharpless NE. 2010. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene :. [PubMed: 20697345]  [MGI Ref ID J:164588]

Montero JC; Esparis-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocana A; Pandiella A. 2014. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 33(2):148-56. [PubMed: 23246963]  [MGI Ref ID J:204879]

Moral M; Segrelles C; Lara MF; Martinez-Cruz AB; Lorz C; Santos M; Garcia-Escudero R; Lu J; Kiguchi K; Buitrago A; Costa C; Saiz C; Rodriguez-Peralto JL; Martinez-Tello FJ; Rodriguez-Pinilla M; Sanchez-Cespedes M; Garin M; Grande T; Bravo A; DiGiovanni J; Paramio JM. 2009. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69(3):1099-108. [PubMed: 19176372]  [MGI Ref ID J:144831]

Morandell S; Reinhardt HC; Cannell IG; Kim JS; Ruf DM; Mitra T; Couvillon AD; Jacks T; Yaffe MB. 2013. A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo. Cell Rep 5(4):868-77. [PubMed: 24239348]  [MGI Ref ID J:203686]

Morton JP; Klimstra DS; Mongeau ME; Lewis BC. 2008. Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Pathol 172(4):1081-7. [PubMed: 18310506]  [MGI Ref ID J:133144]

Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ. 2010. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107(1):246-51. [PubMed: 20018721]  [MGI Ref ID J:156461]

Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS. 2011. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30(32):3522-36. [PubMed: 21423204]  [MGI Ref ID J:174632]

Mullany LK; Liu Z; King ER; Wong KK; Richards JS. 2012. Wild-type tumor repressor protein 53 (Trp53) promotes ovarian cancer cell survival. Endocrinology 153(4):1638-48. [PubMed: 22396451]  [MGI Ref ID J:183892]

Mullany LK; Liu Z; Wong KK; Deneke V; Ren YA; Herron A; Richards JS. 2014. Tumor repressor protein 53 and steroid hormones provide a new paradigm for ovarian cancer metastases. Mol Endocrinol 28(1):127-37. [PubMed: 24264574]  [MGI Ref ID J:211895]

Mutsaers AJ; Ng AJ; Baker EK; Russell MR; Chalk AM; Wall M; Liddicoat BJ; Ho PW; Slavin JL; Goradia A; Martin TJ; Purton LE; Dickins RA; Walkley CR. 2013. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone 55(1):166-78. [PubMed: 23486187]  [MGI Ref ID J:199542]

Navas C; Hernandez-Porras I; Schuhmacher AJ; Sibilia M; Guerra C; Barbacid M. 2012. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22(3):318-30. [PubMed: 22975375]  [MGI Ref ID J:192907]

Nishijo K; Chen QR; Zhang L; McCleish AT; Rodriguez A; Cho MJ; Prajapati SI; Gelfond JA; Chisholm GB; Michalek JE; Aronow BJ; Barr FG; Randall RL; Ladanyi M; Qualman SJ; Rubin BP; LeGallo RD; Wang C; Khan J; Keller C. 2009. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 69(7):2902-11. [PubMed: 19339268]  [MGI Ref ID J:147341]

Nishijo K; Hosoyama T; Bjornson CR; Schaffer BS; Prajapati SI; Bahadur AN; Hansen MS; Blandford MC; McCleish AT; Rubin BP; Epstein JA; Rando TA; Capecchi MR; Keller C. 2009. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J 23(8):2681-90. [PubMed: 19332644]  [MGI Ref ID J:157754]

Niu W; Zou Y; Shen C; Zhang CL. 2011. Activation of Postnatal Neural Stem Cells Requires Nuclear Receptor TLX. J Neurosci 31(39):13816-28. [PubMed: 21957244]  [MGI Ref ID J:176124]

Nolan-Stevaux O; Lau J; Truitt ML; Chu GC; Hebrok M; Fernandez-Zapico ME; Hanahan D. 2009. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev 23(1):24-36. [PubMed: 19136624]  [MGI Ref ID J:143478]

Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M. 2013. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia. Oncogene 32(33):3867-76. [PubMed: 22945649]  [MGI Ref ID J:199980]

O'Dell MR; Huang JL; Whitney-Miller CL; Deshpande V; Rothberg P; Grose V; Rossi RM; Zhu AX; Land H; Bardeesy N; Hezel AF. 2012. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 72(6):1557-67. [PubMed: 22266220]  [MGI Ref ID J:184949]

Ohshima-Hosoyama S; Hosoyama T; Nelon LD; Keller C. 2010. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochem Biophys Res Commun 399(4):727-32. [PubMed: 20692232]  [MGI Ref ID J:164896]

Oliver TG; Mercer KL; Sayles LC; Burke JR; Mendus D; Lovejoy KS; Cheng MH; Subramanian A; Mu D; Powers S; Crowley D; Bronson RT; Whittaker CA; Bhutkar A; Lippard SJ; Golub T; Thomale J; Jacks T; Sweet-Cordero EA. 2010. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24(8):837-52. [PubMed: 20395368]  [MGI Ref ID J:159101]

Olson P; Chu GC; Perry SR; Nolan-Stevaux O; Hanahan D. 2011. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc Natl Acad Sci U S A 108(49):E1275-84. [PubMed: 22084065]  [MGI Ref ID J:180399]

Park KS; Martelotto LG; Peifer M; Sos ML; Karnezis AN; Mahjoub MR; Bernard K; Conklin JF; Szczepny A; Yuan J; Guo R; Ospina B; Falzon J; Bennett S; Brown TJ; Markovic A; Devereux WL; Ocasio CA; Chen JK; Stearns T; Thomas RK; Dorsch M; Buonamici S; Watkins DN; Peacock CD; Sage J. 2011. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med 17(11):1504-8. [PubMed: 21983857]  [MGI Ref ID J:178123]

Perets R; Wyant GA; Muto KW; Bijron JG; Poole BB; Chin KT; Chen JY; Ohman AW; Stepule CD; Kwak S; Karst AM; Hirsch MS; Setlur SR; Crum CP; Dinulescu DM; Drapkin R. 2013. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24(6):751-65. [PubMed: 24332043]  [MGI Ref ID J:207621]

Perez BA; Ghafoori AP; Lee CL; Johnston SM; Li Y; Moroshek JG; Ma Y; Mukherjee S; Kim Y; Badea CT; Kirsch DG. 2013. Assessing the radiation response of lung cancer with different gene mutations using genetically engineered mice. Front Oncol 3:72. [PubMed: 23565506]  [MGI Ref ID J:195492]

Pribluda A; Elyada E; Wiener Z; Hamza H; Goldstein RE; Biton M; Burstain I; Morgenstern Y; Brachya G; Billauer H; Biton S; Snir-Alkalay I; Vucic D; Schlereth K; Mernberger M; Stiewe T; Oren M; Alitalo K; Pikarsky E; Ben-Neriah Y. 2013. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24(2):242-56. [PubMed: 23890787]  [MGI Ref ID J:202528]

Puzio-Kuter AM; Castillo-Martin M; Kinkade CW; Wang X; Shen TH; Matos T; Shen MM; Cordon-Cardo C; Abate-Shen C. 2009. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6):675-80. [PubMed: 19261747]  [MGI Ref ID J:146760]

Quartuccio SM; Lantvit DD; Bosland MC; Burdette JE. 2013. Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas. PLoS One 8(5):e65067. [PubMed: 23741457]  [MGI Ref ID J:200783]

Quinn BA; Brake T; Hua X; Baxter-Jones K; Litwin S; Ellenson LH; Connolly DC. 2009. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 4(12):e8404. [PubMed: 20046879]  [MGI Ref ID J:155938]

Raimondi AR; Molinolo A; Gutkind JS. 2009. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69(10):4159-66. [PubMed: 19435901]  [MGI Ref ID J:148476]

Rajurkar M; De Jesus-Monge WE; Driscoll DR; Appleman VA; Huang H; Cotton JL; Klimstra DS; Zhu LJ; Simin K; Xu L; McMahon AP; Lewis BC; Mao J. 2012. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc Natl Acad Sci U S A 109(17):E1038-47. [PubMed: 22493246]  [MGI Ref ID J:183841]

Reardon SN; King ML; MacLean JA 2nd; Mann JL; DeMayo FJ; Lydon JP; Hayashi K. 2012. CDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterus. Biol Reprod 86(5):141, 1-10. [PubMed: 22378759]  [MGI Ref ID J:185830]

Rhim AD; Mirek ET; Aiello NM; Maitra A; Bailey JM; McAllister F; Reichert M; Beatty GL; Rustgi AK; Vonderheide RH; Leach SD; Stanger BZ. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2):349-61. [PubMed: 22265420]  [MGI Ref ID J:181291]

Robinson G; Parker M; Kranenburg TA; Lu C; Chen X; Ding L; Phoenix TN; Hedlund E; Wei L; Zhu X; Chalhoub N; Baker SJ; Huether R; Kriwacki R; Curley N; Thiruvenkatam R; Wang J; Wu G; Rusch M; Hong X; Becksfort J; Gupta P; Ma J; Easton J; Vadodaria B; Onar-Thomas A; Lin T; Li S; Pounds S; Paugh S; Zhao D; Kawauchi D; Roussel MF; Finkelstein D; Ellison DW; Lau CC; Bouffet E; Hassall T; Gururangan S; Cohn R; Fulton RS; Fulton LL; Dooling DJ; Ochoa K; Gajjar A; Mardis ER; Wilson RK; Downing JR; Zhang J; Gilber. 2012. Novel mutations target distinct subgroups of medulloblastoma. Nature 488(7409):43-8. [PubMed: 22722829]  [MGI Ref ID J:186709]

Rodriguez E; Mannion L; D'Santos P; Griffiths M; Arends MJ; Brindle KM; Lyons SK. 2014. Versatile and enhanced tumour modelling in mice via somatic cell transduction. J Pathol 232(4):449-57. [PubMed: 24307564]  [MGI Ref ID J:208063]

Rommel PC; Bosque D; Gitlin AD; Croft GF; Heintz N; Casellas R; Nussenzweig MC; Kriaucionis S; Robbiani DF. 2013. Fate mapping for activation-induced cytidine deaminase (AID) marks non-lymphoid cells during mouse development. PLoS One 8(7):e69208. [PubMed: 23861962]  [MGI Ref ID J:204283]

Rosenfeldt MT; O'Prey J; Morton JP; Nixon C; MacKay G; Mrowinska A; Au A; Rai TS; Zheng L; Ridgway R; Adams PD; Anderson KI; Gottlieb E; Sansom OJ; Ryan KM. 2013. p53 status determines the role of autophagy in pancreatic tumour development. Nature 504(7479):296-300. [PubMed: 24305049]  [MGI Ref ID J:207920]

Rottenberg S; Nygren AO; Pajic M; van Leeuwen FW; van der Heijden I; van de Wetering K; Liu X; de Visser KE; Gilhuijs KG; van Tellingen O; Schouten JP; Jonkers J; Borst P. 2007. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104(29):12117-22. [PubMed: 17626183]  [MGI Ref ID J:126564]

Rottenberg S; Vollebergh MA; de Hoon B; de Ronde J; Schouten PC; Kersbergen A; Zander SA; Pajic M; Jaspers JE; Jonkers M; Loden M; Sol W; van der Burg E; Wesseling J; Gillet JP; Gottesman MM; Gribnau J; Wessels L; Linn SC; Jonkers J; Borst P. 2012. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res 72(9):2350-61. [PubMed: 22396490]  [MGI Ref ID J:185752]

Rowh MA; Demicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH. 2011. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations. Oncogene 30(47):4757-64. [PubMed: 21625223]  [MGI Ref ID J:178570]

Rubin BP; Nishijo K; Chen HI; Yi X; Schuetze DP; Pal R; Prajapati SI; Abraham J; Arenkiel BR; Chen QR; Davis S; McCleish AT; Capecchi MR; Michalek JE; Zarzabal LA; Khan J; Yu Z; Parham DM; Barr FG; Meltzer PS; Chen Y; Keller C. 2011. Evidence for an Unanticipated Relationship between Undifferentiated Pleomorphic Sarcoma and Embryonal Rhabdomyosarcoma. Cancer Cell 19(2):177-91. [PubMed: 21316601]  [MGI Ref ID J:169449]

Rubio R; Garcia-Castro J; Gutierrez-Aranda I; Paramio J; Santos M; Catalina P; Leone PE; Menendez P; Rodriguez R. 2010. Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 70(10):4185-94. [PubMed: 20442289]  [MGI Ref ID J:160565]

Saifudeen Z; Dipp S; Stefkova J; Yao X; Lookabaugh S; El-Dahr SS. 2009. p53 regulates metanephric development. J Am Soc Nephrol 20(11):2328-37. [PubMed: 19729440]  [MGI Ref ID J:166316]

Samano AK; Ohshima-Hosoyama S; Whitney TG; Prajapati SI; Kilcoyne A; Taniguchi E; Morgan WW; Nelon LD; Lin AL; Togao O; Jung I; Rubin BP; Nowak BM; Duong TQ; Keller C. 2010. Functional evaluation of therapeutic response for a mouse model of medulloblastoma. Transgenic Res 19(5):829-40. [PubMed: 20107895]  [MGI Ref ID J:164746]

Sasajima J; Mizukami Y; Sugiyama Y; Nakamura K; Kawamoto T; Koizumi K; Fujii R; Motomura W; Sato K; Suzuki Y; Tanno S; Fujiya M; Sasaki K; Shimizu N; Karasaki H; Kono T; Kawabe JI; Ii M; Yoshiara H; Kamiyama N; Ashida T; Bardeesy N; Chung DC; Kohgo Y. 2010. Transplanting Normal Vascular Proangiogenic Cells to Tumor-Bearing Mice Triggers Vascular Remodeling and Reduces Hypoxia in Tumors. Cancer Res 70(15):6283-6292. [PubMed: 20631070]  [MGI Ref ID J:162233]

Sasaki M; Knobbe CB; Itsumi M; Elia AJ; Harris IS; Chio II; Cairns RA; McCracken S; Wakeham A; Haight J; Ten AY; Snow B; Ueda T; Inoue S; Yamamoto K; Ko M; Rao A; Yen KE; Su SM; Mak TW. 2012. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes Dev 26(18):2038-49. [PubMed: 22925884]  [MGI Ref ID J:187697]

Savic V; Yin B; Maas NL; Bredemeyer AL; Carpenter AC; Helmink BA; Yang-Iott KS; Sleckman BP; Bassing CH. 2009. Formation of dynamic gamma-H2AX domains along broken DNA strands is distinctly regulated by ATM and MDC1 and dependent upon H2AX densities in chromatin. Mol Cell 34(3):298-310. [PubMed: 19450528]  [MGI Ref ID J:150434]

Sayin VI; Ibrahim MX; Larsson E; Nilsson JA; Lindahl P; Bergo MO. 2014. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 6(221):221ra15. [PubMed: 24477002]  [MGI Ref ID J:212506]

Scarlett UK; Rutkowski MR; Rauwerdink AM; Fields J; Escovar-Fadul X; Baird J; Cubillos-Ruiz JR; Jacobs AC; Gonzalez JL; Weaver J; Fiering S; Conejo-Garcia JR. 2012. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 209(3):495-506. [PubMed: 22351930]  [MGI Ref ID J:182506]

Schackmann RC; Klarenbeek S; Vlug EJ; Stelloo S; van Amersfoort M; Tenhagen M; Braumuller TM; Vermeulen JF; van der Groep P; Peeters T; van der Wall E; van Diest PJ; Jonkers J; Derksen PW. 2013. Loss of p120-Catenin Induces Metastatic Progression of Breast Cancer by Inducing Anoikis Resistance and Augmenting Growth Factor Receptor Signaling. Cancer Res 73(15):4937-49. [PubMed: 23733751]  [MGI Ref ID J:199571]

Schackmann RC; van Amersfoort M; Haarhuis JH; Vlug EJ; Halim VA; Roodhart JM; Vermaat JS; Voest EE; van der Groep P; van Diest PJ; Jonkers J; Derksen PW. 2011. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121(8):3176-88. [PubMed: 21747168]  [MGI Ref ID J:176161]

Schaffer BE; Park KS; Yiu G; Conklin JF; Lin C; Burkhart DL; Karnezis AN; Sweet-Cordero EA; Sage J. 2010. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 70(10):3877-83. [PubMed: 20406986]  [MGI Ref ID J:160148]

Schwitalla S; Ziegler PK; Horst D; Becker V; Kerle I; Begus-Nahrmann Y; Lechel A; Rudolph KL; Langer R; Slotta-Huspenina J; Bader FG; Prazeres da Costa O; Neurath MF; Meining A; Kirchner T; Greten FR. 2013. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23(1):93-106. [PubMed: 23273920]  [MGI Ref ID J:194357]

Shackelford DB; Abt E; Gerken L; Vasquez DS; Seki A; Leblanc M; Wei L; Fishbein MC; Czernin J; Mischel PS; Shaw RJ. 2013. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23(2):143-58. [PubMed: 23352126]  [MGI Ref ID J:194330]

Shai A; Pitot HC; Lambert PF. 2008. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 68(8):2622-31. [PubMed: 18413729]  [MGI Ref ID J:133964]

Shakhova O; Leung C; van Montfort E; Berns A; Marino S. 2006. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res 66(10):5190-200. [PubMed: 16707443]  [MGI Ref ID J:109060]

Shanker A; Brooks AD; Jacobsen KM; Wine JW; Wiltrout RH; Yagita H; Sayers TJ. 2009. Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity. Cancer Res 69(16):6615-23. [PubMed: 19654302]  [MGI Ref ID J:151764]

Shimizu I; Yoshida Y; Katsuno T; Tateno K; Okada S; Moriya J; Yokoyama M; Nojima A; Ito T; Zechner R; Komuro I; Kobayashi Y; Minamino T. 2012. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab 15(1):51-64. [PubMed: 22225876]  [MGI Ref ID J:182322]

Shimizu I; Yoshida Y; Moriya J; Nojima A; Uemura A; Kobayashi Y; Minamino T. 2013. Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. Cell Metab 18(4):491-504. [PubMed: 24093674]  [MGI Ref ID J:206006]

Silvis MR; Kreger BT; Lien WH; Klezovitch O; Rudakova GM; Camargo FD; Lantz DM; Seykora JT; Vasioukhin V. 2011. alpha-catenin is a tumor suppressor that controls cell accumulation by regulating the localization and activity of the transcriptional coactivator Yap1. Sci Signal 4(174):ra33. [PubMed: 21610251]  [MGI Ref ID J:185995]

Siwko SK; Bu W; Gutierrez C; Lewis B; Jechlinger M; Schaffhausen B; Li Y. 2008. Lentivirus-mediated oncogene introduction into mammary cells in vivo induces tumors. Neoplasia 10(7):653-62, 1 p following 662. [PubMed: 18592025]  [MGI Ref ID J:140428]

Snyder EL; Watanabe H; Magendantz M; Hoersch S; Chen TA; Wang DG; Crowley D; Whittaker CA; Meyerson M; Kimura S; Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50(2):185-99. [PubMed: 23523371]  [MGI Ref ID J:198227]

Song H; Yao E; Lin C; Gacayan R; Chen MH; Chuang PT. 2012. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis. Proc Natl Acad Sci U S A 109(43):17531-6. [PubMed: 23047698]  [MGI Ref ID J:190366]

Sotiropoulou PA; Karambelas AE; Debaugnies M; Candi A; Bouwman P; Moers V; Revenco T; Rocha AS; Sekiguchi K; Jonkers J; Blanpain C. 2013. BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny. Genes Dev 27(1):39-51. [PubMed: 23271346]  [MGI Ref ID J:192592]

Spehlmann ME; Manthey CF; Dann SM; Hanson E; Sandhu SS; Liu LY; Abdelmalak FK; Diamanti MA; Retzlaff K; Scheller J; Rose-John S; Greten FR; Wang JY; Eckmann L. 2013. Trp53 deficiency protects against acute intestinal inflammation. J Immunol 191(2):837-47. [PubMed: 23772033]  [MGI Ref ID J:204954]

Stopczynski RE; Normolle DP; Hartman DJ; Ying H; DeBerry JJ; Bielefeldt K; Rhim AD; DePinho RA; Albers KM; Davis BM. 2014. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res 74(6):1718-27. [PubMed: 24448244]  [MGI Ref ID J:208150]

Sun H; Wang Y; Chinnam M; Zhang X; Hayward SW; Foster BA; Nikitin AY; Wills M; Goodrich DW. 2011. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc Natl Acad Sci U S A 108(2):704-9. [PubMed: 21187395]  [MGI Ref ID J:169702]

Sutherland KD; Proost N; Brouns I; Adriaensen D; Song JY; Berns A. 2011. Cell of origin of small cell lung cancer: inactivation of Trp53 and rb1 in distinct cell types of adult mouse lung. Cancer Cell 19(6):754-64. [PubMed: 21665149]  [MGI Ref ID J:173560]

Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A. 2014. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A 111(13):4952-7. [PubMed: 24586047]  [MGI Ref ID J:207396]

Szabova L; Yin C; Bupp S; Guerin TM; Schlomer JJ; Householder DB; Baran ML; Yi M; Song Y; Sun W; McDunn JE; Martin PL; Van Dyke T; Difilippantonio S. 2012. Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72(16):4141-53. [PubMed: 22617326]  [MGI Ref ID J:189304]

Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK. 2013. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One 8(11):e80885. [PubMed: 24260500]  [MGI Ref ID J:206730]

Tang JY; Xiao TZ; Oda Y; Chang KS; Shpall E; Wu A; So PL; Hebert J; Bikle D; Epstein EH Jr. 2011. Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas. Cancer Prev Res (Phila) 4(5):744-51. [PubMed: 21436386]  [MGI Ref ID J:194585]

Taniguchi E; Cho MJ; Arenkiel BR; Hansen MS; Rivera OJ; McCleish AT; Qualman SJ; Guttridge DC; Scott MP; Capecchi MR; Keller C. 2009. Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. Pediatr Blood Cancer 53(2):136-44. [PubMed: 19213072]  [MGI Ref ID J:159972]

Timpson P; McGhee EJ; Morton JP; von Kriegsheim A; Schwarz JP; Karim SA; Doyle B; Quinn JA; Carragher NO; Edward M; Olson MF; Frame MC; Brunton VG; Sansom OJ; Anderson KI. 2011. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res 71(3):747-57. [PubMed: 21266354]  [MGI Ref ID J:169401]

Ting DT; Lipson D; Paul S; Brannigan BW; Akhavanfard S; Coffman EJ; Contino G; Deshpande V; Iafrate AJ; Letovsky S; Rivera MN; Bardeesy N; Maheswaran S; Haber DA. 2011. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 331(6017):593-6. [PubMed: 21233348]  [MGI Ref ID J:168148]

Tonks ID; Mould AW; Schroder WA; Cotterill A; Hayward NK; Walker GJ; Kay GF. 2010. Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia 12(3):235-43. [PubMed: 20234817]  [MGI Ref ID J:162038]

Torchia EC; Caulin C; Acin S; Terzian T; Kubick BJ; Box NF; Roop DR. 2012. Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene 31(21):2680-90. [PubMed: 21963848]  [MGI Ref ID J:186136]

Tornovsky-Babeay S; Dadon D; Ziv O; Tzipilevich E; Kadosh T; Schyr-Ben Haroush R; Hija A; Stolovich-Rain M; Furth-Lavi J; Granot Z; Porat S; Philipson LH; Herold KC; Bhatti TR; Stanley C; Ashcroft FM; In't Veld P; Saada A; Magnuson MA; Glaser B; Dor Y. 2014. Type 2 diabetes and congenital hyperinsulinism cause DNA double-strand breaks and p53 activity in beta cells. Cell Metab 19(1):109-21. [PubMed: 24332968]  [MGI Ref ID J:210493]

Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M. 2013. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res 73(21):6448-61. [PubMed: 24019382]  [MGI Ref ID J:204513]

Uziel T; Zindy F; Xie S; Lee Y; Forget A; Magdaleno S; Rehg JE; Calabrese C; Solecki D; Eberhart CG; Sherr SE; Plimmer S; Clifford SC; Hatten ME; McKinnon PJ; Gilbertson RJ; Curran T; Sherr CJ; Roussel MF. 2005. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 19(22):2656-67. [PubMed: 16260494]  [MGI Ref ID J:102702]

Vooijs M; Jonkers J; Berns A. 2001. A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep 2(4):292-7. [PubMed: 11306549]  [MGI Ref ID J:80160]

Walkley CR; Qudsi R; Sankaran VG; Perry JA; Gostissa M; Roth SI; Rodda SJ; Snay E; Dunning P; Fahey FH; Alt FW; McMahon AP; Orkin SH. 2008. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 22(12):1662-76. [PubMed: 18559481]  [MGI Ref ID J:136693]

Wang GY; So PL; Wang L; Libove E; Wang J; Epstein EH Jr. 2011. Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis. J Invest Dermatol 131(11):2298-305. [PubMed: 21833014]  [MGI Ref ID J:182174]

Wang GY; Wang J; Mancianti ML; Epstein EH Jr. 2011. Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice. Cancer Cell 19(1):114-24. [PubMed: 21215705]  [MGI Ref ID J:168256]

Wei H; Gan B; Wu X; Guan JL. 2009. Inactivation of FIP200 leads to inflammatory skin disorder, but not tumorigenesis, in conditional knock-out mouse models. J Biol Chem 284(9):6004-13. [PubMed: 19106106]  [MGI Ref ID J:147901]

Weiss WA; Israel M; Cobbs C; Holland E; James CD; Louis DN; Marks C; McClatchey AI; Roberts T; Van Dyke T; Wetmore C; Chiu IM; Giovannini M; Guha A; Higgins RJ; Marino S; Radovanovic I; Reilly K; Aldape K. 2002. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 21(49):7453-63. [PubMed: 12386807]  [MGI Ref ID J:79667]

Westerman BA; Blom M; Tanger E; van der Valk M; Song JY; van Santen M; Gadiot J; Cornelissen-Steijger P; Zevenhoven J; Prosser HM; Uren A; Aronica E; van Lohuizen M. 2012. GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors. PLoS One 7(5):e35943. [PubMed: 22574128]  [MGI Ref ID J:187257]

White AC; Khuu JK; Dang CY; Hu J; Tran KV; Liu A; Gomez S; Zhang Z; Yi R; Scumpia P; Grigorian M; Lowry WE. 2014. Stem cell quiescence acts as a tumour suppressor in squamous tumours. Nat Cell Biol 16(1):99-107. [PubMed: 24335650]  [MGI Ref ID J:208368]

White AC; Tran K; Khuu J; Dang C; Cui Y; Binder SW; Lowry WE. 2011. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc Natl Acad Sci U S A 108(18):7425-30. [PubMed: 21502519]  [MGI Ref ID J:172216]

Wijnhoven SW; Zwart E; Speksnijder EN; Beems RB; Olive KP; Tuveson DA; Jonkers J; Schaap MM; van den Berg J; Jacks T; van Steeg H; de Vries A. 2005. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 65(18):8166-73. [PubMed: 16166291]  [MGI Ref ID J:101617]

Wiley LA; Rajagopal R; Dattilo LK; Beebe DC. 2011. The tumor suppressor gene Trp53 protects the mouse lens against posterior subcapsular cataracts and the BMP receptor Acvr1 acts as a tumor suppressor in the lens. Dis Model Mech 4(4):484-95. [PubMed: 21504908]  [MGI Ref ID J:174241]

Winslow MM; Dayton TL; Verhaak RG; Kim-Kiselak C; Snyder EL; Feldser DM; Hubbard DD; DuPage MJ; Whittaker CA; Hoersch S; Yoon S; Crowley D; Bronson RT; Chiang DY; Meyerson M; Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473(7345):101-4. [PubMed: 21471965]  [MGI Ref ID J:171810]

Wu R; Baker SJ; Hu TC; Norman KM; Fearon ER; Cho KR. 2013. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. Am J Pathol 182(4):1391-9. [PubMed: 23499052]  [MGI Ref ID J:195346]

Xing D; Scangas G; Nitta M; He L; Xu X; Ioffe YJ; Aspuria PJ; Hedvat CY; Anderson ML; Oliva E; Karlan BY; Mohapatra G; Orsulic S. 2009. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res 69(21):8231-5. [PubMed: 19843854]  [MGI Ref ID J:153954]

Xiong S; Van Pelt CS; Elizondo-Fraire AC; Fernandez-Garcia B; Lozano G. 2007. Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation 115(23):2925-30. [PubMed: 17533180]  [MGI Ref ID J:137114]

Xu C; Fillmore CM; Koyama S; Wu H; Zhao Y; Chen Z; Herter-Sprie GS; Akbay EA; Tchaicha JH; Altabef A; Reibel JB; Walton Z; Ji H; Watanabe H; Janne PA; Castrillon DH; Rustgi AK; Bass AJ; Freeman GJ; Padera RF; Dranoff G; Hammerman PS; Kim CF; Wong KK. 2014. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 25(5):590-604. [PubMed: 24794706]  [MGI Ref ID J:210599]

Yamashita M; Nitta E; Nagamatsu G; Ikushima YM; Hosokawa K; Arai F; Suda T. 2013. Nucleostemin is indispensable for the maintenance and genetic stability of hematopoietic stem cells. Biochem Biophys Res Commun 441(1):196-201. [PubMed: 24140061]  [MGI Ref ID J:211519]

Yang X; La Rosa FG; Genova EE; Huber K; Schaack J; Degregori J; Serkova NJ; Li Y; Su LJ; Kessler E; Flaig TW. 2013. Simultaneous activation of Kras and inactivation of p53 induces soft tissue sarcoma and bladder urothelial hyperplasia. PLoS One 8(9):e74809. [PubMed: 24058630]  [MGI Ref ID J:207342]

Yin B; Savic V; Juntilla MM; Bredemeyer AL; Yang-Iott KS; Helmink BA; Koretzky GA; Sleckman BP; Bassing CH. 2009. Histone H2AX stabilizes broken DNA strands to suppress chromosome breaks and translocations during V(D)J recombination. J Exp Med 206(12):2625-39. [PubMed: 19887394]  [MGI Ref ID J:155456]

Yin B; Yang-Iott KS; Chao LH; Bassing CH. 2011. Cellular context-dependent effects of H2ax and p53 deletion on the development of thymic lymphoma. Blood 117(1):175-85. [PubMed: 20947684]  [MGI Ref ID J:168421]

Ying H; Kimmelman AC; Lyssiotis CA; Hua S; Chu GC; Fletcher-Sananikone E; Locasale JW; Son J; Zhang H; Coloff JL; Yan H; Wang W; Chen S; Viale A; Zheng H; Paik JH; Lim C; Guimaraes AR; Martin ES; Chang J; Hezel AF; Perry SR; Hu J; Gan B; Xiao Y; Asara JM; Weissleder R; Wang YA; Chin L; Cantley LC; DePinho RA. 2012. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-70. [PubMed: 22541435]  [MGI Ref ID J:186194]

Yokoyama M; Okada S; Nakagomi A; Moriya J; Shimizu I; Nojima A; Yoshida Y; Ichimiya H; Kamimura N; Kobayashi Y; Ohta S; Fruttiger M; Lozano G; Minamino T. 2014. Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. Cell Rep 7(5):1691-703. [PubMed: 24857662]  [MGI Ref ID J:211787]

Young NP; Crowley D; Jacks T. 2011. Uncoupling Cancer Mutations Reveals Critical Timing of p53 Loss in Sarcomagenesis. Cancer Res 71(11):4040-7. [PubMed: 21512139]  [MGI Ref ID J:172206]

Yu Y; Wang J; Khaled W; Burke S; Li P; Chen X; Yang W; Jenkins NA; Copeland NG; Zhang S; Liu P. 2012. Bcl11a is essential for lymphoid development and negatively regulates p53. J Exp Med 209(13):2467-83. [PubMed: 23230003]  [MGI Ref ID J:194616]

Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S. 2010. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Res 70(4):1700-10. [PubMed: 20145144]  [MGI Ref ID J:157686]

Zhang J; Schweers B; Dyer MA. 2004. The first knockout mouse model of retinoblastoma. Cell Cycle 3(7):952-9. [PubMed: 15190215]  [MGI Ref ID J:103618]

Zhang Y; Yan W; Collins MA; Bednar F; Rakshit S; Zetter BR; Stanger BZ; Chung I; Rhim AD; di Magliano MP. 2013. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 73(20):6359-74. [PubMed: 24097820]  [MGI Ref ID J:205411]

Zhao H; Ayrault O; Zindy F; Kim JH; Roussel MF. 2008. Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev 22(6):722-727. [PubMed: 18347090]  [MGI Ref ID J:132983]

Zhao H; Bauzon F; Fu H; Lu Z; Cui J; Nakayama K; Nakayama KI; Locker J; Zhu L. 2013. Skp2 deletion unmasks a p27 safeguard that blocks tumorigenesis in the absence of pRb and p53 tumor suppressors. Cancer Cell 24(5):645-59. [PubMed: 24229711]  [MGI Ref ID J:206734]

Zhao Z; Zuber J; Diaz-Flores E; Lintault L; Kogan SC; Shannon K; Lowe SW. 2010. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 24(13):1389-402. [PubMed: 20595231]  [MGI Ref ID J:161357]

Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA. 2008. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129-33. [PubMed: 18948956]  [MGI Ref ID J:140704]

Zheng Y; de la Cruz CC; Sayles LC; Alleyne-Chin C; Vaka D; Knaak TD; Bigos M; Xu Y; Hoang CD; Shrager JB; Fehling HJ; French D; Forrest W; Jiang Z; Carano RA; Barck KH; Jackson EL; Sweet-Cordero EA. 2013. A Rare Population of CD24(+)ITGB4(+)Notch(hi) Cells Drives Tumor Propagation in NSCLC and Requires Notch3 for Self-Renewal. Cancer Cell 24(1):59-74. [PubMed: 23845442]  [MGI Ref ID J:199306]

Zhou Z; Flesken-Nikitin A; Corney DC; Wang W; Goodrich DW; Roy-Burman P; Nikitin AY. 2006. Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer. Cancer Res 66(16):7889-98. [PubMed: 16912162]  [MGI Ref ID J:112104]

Zhou Z; Flesken-Nikitin A; Nikitin AY. 2007. Prostate Cancer Associated with p53 and Rb Deficiency Arises from the Stem/Progenitor Cell-Enriched Proximal Region of Prostatic Ducts. Cancer Res 67(12):5683-90. [PubMed: 17553900]  [MGI Ref ID J:122263]

Zhu Z; Aref AR; Cohoon TJ; Barbie TU; Imamura Y; Yang S; Moody SE; Shen RR; Schinzel AC; Thai TC; Reibel JB; Tamayo P; Godfrey JT; Qian ZR; Page AN; Maciag K; Chan EM; Silkworth W; Labowsky MT; Rozhansky L; Mesirov JP; Gillanders WE; Ogino S; Hacohen N; Gaudet S; Eck MJ; Engelman JA; Corcoran RB; Wong KK; Hahn WC; Barbie DA. 2014. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 4(4):452-65. [PubMed: 24444711]  [MGI Ref ID J:212507]

Zindy F; Uziel T; Ayrault O; Calabrese C; Valentine M; Rehg JE; Gilbertson RJ; Sherr CJ; Roussel MF. 2007. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 67(6):2676-84. [PubMed: 17363588]  [MGI Ref ID J:120317]

Zou Y; Niu W; Qin S; Downes M; Burns DK; Zhang CL. 2012. The nuclear receptor TLX is required for gliomagenesis within the adult neurogenic niche. Mol Cell Biol 32(23):4811-20. [PubMed: 23028043]  [MGI Ref ID J:192734]

van der Weyden L; Adams DJ. 2013. Cancer of mice and men: old twists and new tails. J Pathol 230(1):4-16. [PubMed: 23436574]  [MGI Ref ID J:196071]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX10

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, heterozygotes may be bred. Homozygotes have a somewhat reduced fertility, but may be bred.
Mating SystemHomozygote x Homozygote         (Female x Male)   13-DEC-11
Diet Information LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $232.00Female or MaleHomozygous for Trp53tm1Brn  
Price per Pair (US dollars $)Pair Genotype
$464.00Homozygous for Trp53tm1Brn x Homozygous for Trp53tm1Brn  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Live Mice

Price per mouse (US dollars $)GenderGenotypes Provided
Individual Mouse $301.60Female or MaleHomozygous for Trp53tm1Brn  
Price per Pair (US dollars $)Pair Genotype
$603.20Homozygous for Trp53tm1Brn x Homozygous for Trp53tm1Brn  

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Repository-Live.
Repository-Live represents an exclusive set of over 1800 unique mouse models across a vast array of research areas. Breeding colonies provide mice for large and small orders and fluctuate in size depending on current research demand. If a strain is not immediately available, you will receive an estimated availability timeframe for your inquiry or order in 2-3 business days. Repository strains typically are delivered at 4 to 8 weeks of age. Requests for specific ages will be noted but not guaranteed and we do not accept age requests for breeder pairs. However, if cohorts of mice (5 or more of one gender) are needed at a specific age range for experiments, we will do our best to accommodate your age request.

Control Information

  Control
   000664 C57BL/6J
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)